Rafael Holdings' Phase 3 NPC trial misses primary endpoint, subgroup hits significance
Trappsol Cyclo showed a directionally favorable but not statistically significant effect on the primary endpoint, while a prespecified subgroup analysis reached significance; Rafael still plans an NDA filing in Q4 2026.
SEC filing